-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pulmonary arterial hypertension (PAH) is a progressive disease, and the survival time of patients is limited
.
Iron deficiency (ID) is related to disease severity and mortality
Researchers retrospectively analyzed the effects of intravenous infusion of carboxymaltose iron (FCM) on the combined ID of stable targeted PAH therapy (ferritin <100 μg/L or ferritin 100-300 μg/L and transferrin saturation [ TSAT] <20%) the iron status of PAH patients and the influence of clinical measures were compared with those of PAH patients without ID
.
Patients with ID received a single dose of FCM (500-1000 mg) infusion
The effect of FCM supplementation on serum iron and ferritin
The effect of FCM supplementation on serum iron and ferritinA total of 117 PAH patients (average 60.
9±16.
1 years old, 64.
1% women) who received stable targeted therapy for ≥3 months with a clearly diagnosed disease were included , of which 58 had ID and 59 had no ID
.
FCM iron supplementation in PAH patients with ID can improve the iron status immediately and last for up to 18 months (the p values of serum iron, ferritin, and TSAT are all <0.
diagnosis
Changes in the six-minute walking distance of the two groups of patients
Changes in the six-minute walking distance of the two groups of patientsAt the 6th and 18th months after FCM infusion, the six-minute walking distance of patients in the FCM group increased from 377.
5±15.
9 meters at baseline to 412.
5±15.
1 meters and 400.
8±14.
5 meters, respectively (p<0.
05)
.
The WHO functional classification and ESC/ERS risk status of patients in the FCM group also improved (p=0.
At the 6th and 18th months after FCM infusion, the six-minute walking distance of patients in the FCM group increased from 377.
PAH-related hospitalization rates before and after intervention in the two groups
PAH-related hospitalization rates before and after intervention in the two groupsFor patients with pulmonary hypertension with iron deficiency, in addition to the treatment of PAH, it seems feasible and safe to correct iron deficiency by supplementing iron outside the stomach and intestines through FCM.
It has a sustained beneficial effect on iron status and may improve the patient’s condition.
Clinical status, reduce hospitalization rate
.
A larger-scale controlled study is needed to verify the results of this study
For patients with pulmonary hypertension with iron deficiency, in addition to the treatment of PAH, it seems feasible and safe to correct iron deficiency by supplementing iron outside the stomach and intestines through FCM.
Original source:
Kramer Tilmann,Wissmüller Max,Natsina Kristiana et al.
Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study in this message